| 1.795 0.035 (1.99%) | 10-14 12:24 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.51  |
1-year : | 2.83 |
| Resists | First : | 2.15 |
Second : | 2.42 |
| Pivot price | 1.96 |
|||
| Supports | First : | 1.72 |
Second : | 1.43 |
| MAs | MA(5) : | 1.86 |
MA(20) : | 2.03 |
| MA(100) : | 2.1  |
MA(250) : | 1.87 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.8 |
D(3) : | 14.4 |
| RSI | RSI(14): 33.6 |
|||
| 52-week | High : | 2.6 | Low : | 1.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IKT ] has closed above bottom band by 12.6%. Bollinger Bands are 3.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.88 - 1.89 | 1.89 - 1.9 |
| Low: | 1.7 - 1.71 | 1.71 - 1.73 |
| Close: | 1.74 - 1.76 | 1.76 - 1.78 |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Wed, 14 Oct 2026
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Hold" at Chardan Capital - MarketBeat
Tue, 13 Oct 2026
Chardan initiates Inhibikase Therapeutics stock with neutral rating By Investing.com - Investing.com Nigeria
Fri, 02 Oct 2026
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fri, 02 Oct 2026
Two new hires receive options to buy up to 128,000 Inhibikase shares - Stock Titan
Thu, 01 Oct 2026
Inhibikase Therapeutics Inc (IKT-Q) Stock Price and News - The Globe and Mail
Wed, 30 Sep 2026
We're Hopeful That Inhibikase Therapeutics (NASDAQ:IKT) Will Use Its Cash Wisely - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 140 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 89.7 (%) |
| Shares Short | 19,430 (K) |
| Shares Short P.Month | 19,490 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -52 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -4.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|